Illumina, Inc. (NASDAQ:ILMN) Shares Sold by State of Alaska Department of Revenue

State of Alaska Department of Revenue decreased its stake in Illumina, Inc. (NASDAQ:ILMN) by 28.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 18,082 shares of the life sciences company’s stock after selling 7,345 shares during the period. State of Alaska Department of Revenue’s holdings in Illumina were worth $2,416,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ILMN. Cetera Investment Advisers boosted its holdings in shares of Illumina by 25.8% in the 2nd quarter. Cetera Investment Advisers now owns 18,384 shares of the life sciences company’s stock valued at $1,919,000 after buying an additional 3,767 shares in the last quarter. CWM LLC boosted its stake in Illumina by 179.8% during the 3rd quarter. CWM LLC now owns 16,207 shares of the life sciences company’s stock worth $2,114,000 after purchasing an additional 10,414 shares during the period. Livforsakringsbolaget Skandia Omsesidigt boosted its stake in Illumina by 323.9% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,047 shares of the life sciences company’s stock worth $136,000 after purchasing an additional 800 shares during the period. Valeo Financial Advisors LLC acquired a new stake in Illumina during the 3rd quarter worth $276,000. Finally, Compagnie Lombard Odier SCmA boosted its stake in Illumina by 2,013.3% during the 3rd quarter. Compagnie Lombard Odier SCmA now owns 1,585 shares of the life sciences company’s stock worth $207,000 after purchasing an additional 1,510 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Canaccord Genuity Group decreased their price target on shares of Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a research note on Friday. UBS Group upped their price objective on shares of Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Robert W. Baird upped their price objective on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Citigroup downgraded shares of Illumina from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $190.00 to $165.00 in a research report on Wednesday, December 11th. Finally, HSBC upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price objective for the company in a research report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $160.15.

Illumina Price Performance

Illumina stock opened at $104.99 on Tuesday. Illumina, Inc. has a 12-month low of $100.08 and a 12-month high of $156.66. The stock has a market capitalization of $16.65 billion, a P/E ratio of -13.67 and a beta of 1.10. The firm’s 50-day moving average is $136.70 and its two-hundred day moving average is $135.56. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 12.59% and a negative net margin of 27.95%. Equities analysts predict that Illumina, Inc. will post 4.42 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.